The broad, long-term goal of this proposal is to position disease modeling as a viable tool for clinical decision making and policy development. The specific goal is to utilize the three complementary surveillance models developed by the CISNET prostate group to address some of the most persistent and pressing policy questions in prostate cancer. In the proposed work we will extend the models to capture downstream outcomes following diagnosis, such as disease recurrence and secondary treatment. The extensions will be informed by some of the largest and richest population-based data sources available and will be validated extensively using these datasets and results from recently published US and European prostate cancer screening trials. The extended models will be used to project the expected costs and benefits of different screening and treatment policies in order to identify those likely to be of most value in practice. The screening policies will consider different ages to start and stop screening, inter-screen intervals, PSA-based criteria for biopsy referral, and combination policies that incorporate novel screening biomarkers. The treatment policies will include immediate versus delayed primary treatment and immediate versus deferred secondary treatment following biochemical failure. We will extensively investigate the ramifications for both disease-specific and other-cause mortality of policies that include hormonal therapy, the most common systemic treatment for suspected or confirmed metastatic disease. Recognizing that different policies may be called for in different subgroups, we will also investigate the need for targeted policies within subpopulations defined by factors known to affect prostate cancer risk and outcomes, namely age, comorbidity, race, and obesity. The proposed work comprehensively covers the continuum of cancer control issues amenable to modeling that face prostate cancer investigators today. We plan to conduct the research using a coordinated comparative modeling approach in which independent models are standardized and made comparable by the use of common inputs and the implementation of common """"""""base case"""""""" scenarios. .

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA157224-04
Application #
8538777
Study Section
Special Emphasis Panel (ZCA1-SRLB-4 (M1))
Program Officer
Stedman, Margaret R
Project Start
2010-09-09
Project End
2015-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
4
Fiscal Year
2013
Total Cost
$1,023,733
Indirect Cost
$190,538
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
de Carvalho, Tiago M; Heijnsdijk, Eveline A M; de Koning, Harry J (2016) Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men. Int J Cancer 138:2522-8
Roth, Joshua A; Gulati, Roman; Gore, John L et al. (2016) Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncol 2:890-8
Carlsson, Sigrid V; de Carvalho, Tiago M; Roobol, Monique J et al. (2016) Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer 122:3386-3393
Etzioni, Ruth; Gulati, Roman (2016) Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them. J Natl Cancer Inst 108:
de Carvalho, Tiago M; Heijnsdijk, Eveline A M; de Koning, Harry J (2015) Screening for prostate cancer in the US? Reduce the harms and keep the benefit. Int J Cancer 136:1600-7
Heijnsdijk, E A M; de Carvalho, T M; Auvinen, A et al. (2015) Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst 107:366
Birnbaum, Jeanette K; Feng, Ziding; Gulati, Roman et al. (2015) Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. Cancer Epidemiol Biomarkers Prev 24:677-82
Ha, Jinkyung; Tsodikov, Alexander (2015) Semiparametric estimation in the proportional hazard model accounting for a misclassified cause of failure. Biometrics 71:941-9
Etzioni, Ruth; Xia, Jing; Hubbard, Rebecca et al. (2014) A reality check for overdiagnosis estimates associated with breast cancer screening. J Natl Cancer Inst 106:
Etzioni, Ruth; Gulati, Roman (2014) RE: A model too far. J Natl Cancer Inst 106:dju058

Showing the most recent 10 out of 39 publications